Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma
- PMID: 35974375
- PMCID: PMC9382740
- DOI: 10.1186/s12967-022-03532-2
Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma
Abstract
Acral melanoma (AM) has unique biology as an aggressive subtype of melanoma. It is a common subtype of melanoma in races with darker skin tones usually diagnosed at a later stage, thereby presenting a worse prognosis compared to cutaneous melanoma. The pathogenesis of acral melanoma differs from cutaneous melanoma, and trauma promotes its development. Compared to cutaneous melanomas, acral melanomas have a significantly lighter mutational burden with more copy number variants. Most acral melanomas are classified as triple wild-type. In contrast to cutaneous melanomas, acral melanomas have a suppressive immune microenvironment. Herein, we reviewed the clinical features, genetic variants, and immune microenvironmental characteristics of limbic melanomas to summarise their unique features.
Keywords: Acral melanoma; Clinical features; Immune microenvironment; Molecular pathology.
© 2022. The Author(s).
Conflict of interest statement
The authors have no conflicts of interest that are directly relevant to the content of this article.
Figures

Similar articles
-
Acral Melanoma: A Review of Its Pathogenesis, Progression, and Management.Biomolecules. 2025 Jan 14;15(1):120. doi: 10.3390/biom15010120. Biomolecules. 2025. PMID: 39858514 Free PMC article. Review.
-
Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.Lab Invest. 2017 Feb;97(2):130-145. doi: 10.1038/labinvest.2016.143. Epub 2017 Jan 9. Lab Invest. 2017. PMID: 28067894
-
Targeted Genomic Profiling of Acral Melanoma.J Natl Cancer Inst. 2019 Oct 1;111(10):1068-1077. doi: 10.1093/jnci/djz005. J Natl Cancer Inst. 2019. PMID: 30657954 Free PMC article.
-
Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.J Invest Dermatol. 2018 Feb;138(2):384-393. doi: 10.1016/j.jid.2017.08.022. Epub 2017 Sep 1. J Invest Dermatol. 2018. PMID: 28870692
-
Managing telomerase and telomere dysfunction in acral melanoma.Pharmacol Res. 2025 May;215:107700. doi: 10.1016/j.phrs.2025.107700. Epub 2025 Mar 15. Pharmacol Res. 2025. PMID: 40097124 Review.
Cited by
-
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial.Signal Transduct Target Ther. 2024 Nov 22;9(1):318. doi: 10.1038/s41392-024-02029-2. Signal Transduct Target Ther. 2024. PMID: 39572525 Free PMC article. Clinical Trial.
-
Editorial: Multidisciplinary treatment and precision medicine for acral and mucosal melanoma.Front Oncol. 2024 May 30;14:1429030. doi: 10.3389/fonc.2024.1429030. eCollection 2024. Front Oncol. 2024. PMID: 38873257 Free PMC article. No abstract available.
-
A distinct subgroup with Schwann-like differentiation presents immune resistance and poor prognosis in plantar melanoma.Theranostics. 2025 Mar 3;15(9):3900-3923. doi: 10.7150/thno.99526. eCollection 2025. Theranostics. 2025. PMID: 40213656 Free PMC article.
-
Clinicopathological features, response patterns, outcomes and BRAF status in patients with advanced acral melanoma: a preliminary Peruvian study.Ecancermedicalscience. 2024 Aug 27;18:1749. doi: 10.3332/ecancer.2024.1749. eCollection 2024. Ecancermedicalscience. 2024. PMID: 39421183 Free PMC article.
-
Clinical characteristics, survival analysis and influencing factors of distant metastasis in patients with acromelanomas: A retrospective study.Medicine (Baltimore). 2024 Jun 7;103(23):e38230. doi: 10.1097/MD.0000000000038230. Medicine (Baltimore). 2024. PMID: 38847674 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical